Analysts at Wall Street Zen have upgraded the rating of Structure Therapeutics (NASDAQ: GPCR) from “sell” to “hold,” as detailed in a report released on Saturday. The move reflects a shift in market sentiment towards the biopharmaceutical company, which focuses on innovative treatments for chronic diseases.
Recent Analyst Ratings and Price Targets
Various analysts have recently shared their perspectives on the company’s stock. HC Wainwright reaffirmed a “buy” rating and set a target price of $60.00 for Structure Therapeutics on November 28. Meanwhile, Morgan Stanley raised its price target from $120.00 to $125.00 while maintaining an “overweight” rating.
In a report on December 8, Stifel Nicolaus increased its price objective from $50.00 to $90.00 and assigned a “buy” rating to the stock. Conversely, Zacks Research downgraded Structure Therapeutics from a “hold” to a “strong sell” rating on October 17. Additionally, Lifesci Capital upgraded its rating to “strong buy” on September 8.
Currently, one research analyst has issued a “strong buy” rating, eleven hold “buy” ratings, and two “sell” ratings for the stock. According to MarketBeat, Structure Therapeutics has an average rating of “moderate buy” with an average target price of $95.78.
Quarterly Earnings Performance
Structure Therapeutics announced its quarterly earnings results on November 6. The company reported earnings per share of ($0.37), which fell short of the consensus estimate of ($0.36) by $0.01. Analysts anticipate that the company will post earnings per share of ($0.82) for the current fiscal year.
Institutional Investor Activity
In recent months, several institutional investors have adjusted their holdings in Structure Therapeutics. The State of Wyoming acquired a new stake in the company during the second quarter, valued at approximately $28,000. EverSource Wealth Advisors LLC significantly increased its position by 530% in the third quarter, now owning 1,071 shares worth around $30,000.
Furthermore, National Bank of Canada FI raised its stake by 1,448.2% in the first quarter, acquiring 2,957 shares valued at $51,000. Assetmark Inc. boosted its stake by 39.9% in the second quarter, owning 2,877 shares worth $60,000. Lastly, PNC Financial Services Group Inc. increased its position by 29.1%, holding 4,415 shares valued at $92,000.
Currently, institutional investors own approximately 91.78% of Structure Therapeutics stock, highlighting strong institutional interest in the company.
About Structure Therapeutics
Structure Therapeutics Inc. is a clinical stage global biopharmaceutical company that develops and delivers novel oral therapeutics aimed at treating a range of chronic diseases with significant unmet medical needs. The company’s lead product candidate, GSBR-1290, is an oral, biased small molecule agonist targeting the glucagon-like peptide-1 receptor, a key therapeutic target for conditions such as type-2 diabetes mellitus and obesity.
As investors continue to monitor the developments at Structure Therapeutics, the company’s evolving landscape and analyst ratings will be crucial in shaping its future trajectory in the biopharmaceutical space.
